Nivolumab for squamous cell carcinoma of head and neck

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 3 Jul 2018: Trial registered, NCT03576417
  2. 10 Oct 2018: Trial started, NCT03576417

The trials

NCT03576417: A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck

State
Under way
Phase
Phase 3
People
680 taking part
Started
10 Oct 2018
Primary completion
Aug 2027
Arms
RT+ cisplatin + nivolumab
Results
None posted
  1. 3 Jul 2018: Trial registered
  2. 10 Oct 2018: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as Nivolumab 3 mg/kg + platinum-based chemotherapy (2 cycles, neoadjuvant), Opdivo, Opdivo qvantig component nivolumab, Opdualag component nivolumab.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.